Literature DB >> 2677314

The problem of model indistinguishability in pharmacokinetics.

K R Godfrey1, M J Chapman.   

Abstract

The problem of model indistinguishability is introduced in the context of linear compartmental models in pharmacokinetics. The two most widely used methods of analyzing model indistinguishability are described. It is shown that as the number of compartments increases, one approach, based on the Laplace transforms of the observations, although conceptually simple, can result in very large numbers of candidate models to be examined for indistinguishability, while the other approach, based on similarity transformations, although systematic, often results in very difficult algebraic expressions. These problems can be eased by the use of some simple geometrical rules, used at the outset of an indistinguishability analysis. The approach is illustrated by application of two 2-compartment drug, 2-compartment metabolite models.

Mesh:

Year:  1989        PMID: 2677314     DOI: 10.1007/bf01059030

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  4 in total

1.  Do you need a pharmacokinetic model, and, if so, which one?

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1975-12

2.  Pharmacokinetics of isoniazid and some metabolites in man.

Authors:  H G Boxenbaum; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

3.  Structural identifiability of "first-pass" models.

Authors:  A Venot; E Walter; Y Lecourtier; A Raksanyi; L Chauvelot-Moachon
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

4.  Two-compartment model for a drug and its metabolite: application to acetylsalicylic acid pharmacokinetics.

Authors:  M Rowland; L Z Benet; S Riegelman
Journal:  J Pharm Sci       Date:  1970-03       Impact factor: 3.534

  4 in total
  5 in total

1.  An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example.

Authors:  Y M Wang; R H Reuning
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

2.  Bootstrapping for pharmacokinetic models: visualization of predictive and parameter uncertainty.

Authors:  C A Hunt; G H Givens; S Guzy
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

3.  Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Authors:  Sameed Ahmed; Miandra Ellis; Hongshan Li; Luca Pallucchini; Andrew M Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-29       Impact factor: 2.745

Review 4.  Identifiability and indistinguishability of nonlinear pharmacokinetic models.

Authors:  K R Godfrey; M J Chapman; S Vajda
Journal:  J Pharmacokinet Biopharm       Date:  1994-06

Review 5.  Statistical considerations in pharmacokinetic study design.

Authors:  J D Powers
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.